Table 1.
Demographics
| Variable | All | ABMR | TCMR | Clinical | None | Control | P |
| No. of patients | 197 | 9 | 10 | 16 | 35 | 127 | 0.59 |
| Male sex, n (%) | 116 (59) | 5 (56) | 6 (60) | 8 (50) | 24 (69) | 73 (57) | |
| Race, n (%) | |||||||
| American Indian or Alaskan native | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0.09 |
| Asian | 5 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (4) | |
| Black | 63 (32) | 6 (67) | 1 (10) | 6 (38) | 12 (34) | 38 (30) | |
| Hispanic/Latino | 22 (11) | 0 (0) | 0 (0) | 2 (12) | 3 (9) | 17 (13) | |
| Native Hawaiian or other Pacific Islander | 2 (1) | 0 (0) | 1 (10) | 0 (0) | 0 (0) | 1 (1) | |
| Other | 12 (6) | 0 (0) | 0 (0) | 0 (0) | 5 (14) | 7 (6) | |
| White | 90 (46) | 3 (33) | 7 (70) | 8 (50) | 13 (37) | 59 (46) | |
| Donor type, n (%) | 0.27 | ||||||
| Deceased donor | 127 (64) | 6 (67) | 7 (70) | 10 (62) | 19 (54) | 85 (67) | |
| Living related | 27 (14) | 3 (33) | 1 (10) | 2 (12) | 3 (9) | 18 (14) | |
| Living unrelated | 41 (21) | 0 (0) | 1 (10) | 4 (25) | 12 (34) | 24 (19) | |
| CMV infection, n (%) | 3 (2) | 1 (11) | 0 (0) | 0 (0) | 0 (0) | 2 (2) | 0.17 |
| BKV infection, n (%) | 13 (7) | 0 (0) | 1 (10) | 4 (25) | 5 (14) | 3 (2) | 0.002 |
| DSA, n (%) | 18 (9) | 9 (100) | 2 (20) | 2 (12) | 5 (14) | 0 (0) | <0.001 |
| Age at enrollment, mean±SD | 50±14 | 52±13 | 38±17 | 52±15 | 51±12 | 50±13 | 0.11 |
| Days post-transplant at time of biopsy, mean±SD | 151±153.2 | 1024±880.5 | 207±281 | 726.5±446.5 | 108.5±132.4 | 135±119 | <0.001 |
| HLA class 1 mismatches, mean±SD | 2.9±1.1 | 2.7±1.5 | 2.9±1.5 | 2.4±1.1 | 3.1±1 | 2.9±1 | 0.28 |
| HLA class 2 mismatches, mean±SD | 1.3±0.7 | 1.1±0.8 | 1.2±0.7 | 1.1±0.9 | 1.4±0.7 | 1.2±0.7 | 0.48 |
Demographic and clinical information for each of the four biopsy groups plus the control group is provided. ABMR, antibody-mediated rejection; TCMR, T cell–mediated rejection; CMV, cytomegalovirus; BKV, BK virus; DSA, donor-specific antibodies.